NASDAQ:AQST
Aquestive Therapeutics (AQST)
Financials 
Technical Analysis 
Sep 2, 2026, 12:00 amThis summary was created by AI, based on 1 opinions in the last 12 months.
Aquestive Therapeutics (AQST-Q) has experienced a significant decline of 43% over the past month, primarily due to concerns surrounding their drug application for Anaphylm. The FDA's recent communication highlighted substantial deficiencies in the application, which raises serious questions about the likelihood of the drug's approval. This development has cast a shadow over the company's future, sowing doubt among investors and analysts alike. Despite the negative news, some experts suggest that holding onto the stock might still be a viable option, as there remains a potential pathway for approval. However, overall confidence in the company has markedly decreased, indicating a cautious outlook going forward.
- «
- ‹
- 1
- ›
- »
Popular Articles
Aquestive Therapeutics (AQST) Frequently Asked Questions
What is Aquestive Therapeutics stock symbol?
Aquestive Therapeutics is a American stock, trading under the symbol AQST (previously AQST-Q on Stockchase) on the NASDAQ (AQST). It is usually referred to as NASDAQ:AQST or AQST
Is Aquestive Therapeutics a buy or a sell?
In the last year, 1 stock analyst issued a Buy, Sell, or Hold rating on AQST (previously AQST-Q on Stockchase). 0 analysts recommended to BUY and 1 analyst recommended to SELL the stock. The latest stock analyst rating is DON'T BUY. Read the latest stock experts' ratings for Aquestive Therapeutics.
Is Aquestive Therapeutics a good investment or a top pick?
Aquestive Therapeutics was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Aquestive Therapeutics.
Why is Aquestive Therapeutics stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Aquestive Therapeutics.
Is Aquestive Therapeutics worth watching?
Aquestive Therapeutics is covered by Stockchase experts and is worth watching.
What is Aquestive Therapeutics stock price?
On 2026-09-02, Aquestive Therapeutics (AQST) stock closed at a price of $5.38.
Is hammered 43% the past month. What went wrong? Last week, the FDA sent them a letter citing big deficiencies in their Anaphylm drug application. This throws into doubt the approval of this drug. That said, don't sell AQST now, because there's a chance of approval. He's far less confident in AQST than before.